Satisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystonia

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 419-423

  Sethi, Kapil D ^a,c   Rodriguez, Ramon ^b   Olayinka, Babajide ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Merz Pharmaceuticals LLC   (United States)

Author keywords

AbobotulinumtoxinA; Botox; Cervical dystonia; Dysport; IncobotulinumtoxinA; OnabotulinumtoxinA; Xeomin

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CANADA; CERVICAL DYSTONIA; CERVICAL DYSTONIA IMPACT PROFILE 58; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRANCE; GERMANY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PATIENT INFORMATION; PATIENT SATISFACTION; QUALITY OF LIFE; RATING SCALE; STRUCTURED QUESTIONNAIRE; SYMPTOM; UNITED STATES; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; CANADA; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; GERMANY; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; TORTICOLLIS; UNITED STATES; YOUNG ADULT;

EID: 84859207456     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.653726     Document Type: Article

References (19)

1. Dauer WT, Burke RE, Greene P, et al. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998;121:547-60
2. Jahanshahi M, Marsden CD. A longitudinal follow-up study of depression, disability, and body concept in torticollis. Behav Neurol 1990;3:233-46
3. Claypool DW, Duane DD, Ilstrup DM, et al. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 1995;10:608-14
4. Jahanshahi M. Psychosocial factors and depression in torticollis. J Psychosom Res 1991;35:493-507
5. Jahanshahi M, Marsden CD. Body concept, disability, and depression in patients with spasmodic torticollis. Behav Neurol 1990;3:117-31
6. Hsiung GY, Das SK, Ranawaya R, et al. Long-Term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-93
7. Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008; 26(1 Suppl):54-65
8. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005:CD003633
9. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64:1949-51
10. Ferreira JJ, Costa J, Coelho M, et al. The management of cervical dystonia. Expert Opin Pharmacother 2007;8:129-40
11. Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics 2009;3:1-7
12. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006;67:2230-2
13. Cano SJ, Warner TT, Linacre JM, et al. Capturing the true burden of dystonia on patients: The Cervical Dystonia Impact Profile (CDIP-58). Neurology 2004;63:1629-33
14. Gudex CM, Hawthorne MR, Butler AG, et al. Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 1998;13:941-6
15. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol 2001;21:85-90
16. Skogseid IM, Roislien J, Claussen B, et al. Long-Term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 2005;20:1604-9
17. Molho ES, Agarwal N, Regan K, et al. Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 2009;24:1384-7
18. Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-Term botulinum toxin A treatment. Eur J Neurol 2005;12:163-70
19. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-7